RT Journal Article
SR Electronic
T1 Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.04.23297559
DO 10.1101/2023.12.04.23297559
A1 Lynce, Filipa
A1 Mainor, Candace
A1 Donahue, Renee N.
A1 Geng, Xue
A1 Jones, Greg
A1 Schlam, Ilana
A1 Wang, Hongkun
A1 Toney, Nicole J.
A1 Jochems, Caroline
A1 Schlom, Jeffrey
A1 Zeck, Jay
A1 Gallagher, Christopher
A1 Nanda, Rita
A1 Graham, Deena
A1 Stringer-Reasor, Erica M
A1 Denduluri, Neelima
A1 Collins, Julie
A1 Chitalia, Ami
A1 Tiwari, Shruti
A1 Nunes, Raquel
A1 Kaltman, Rebecca
A1 Khoury, Katia
A1 Gatti-Mays, Margaret
A1 Tarantino, Paolo
A1 Tolaney, Sara M.
A1 Swain, Sandra M
A1 Pohlmann, Paula
A1 Parsons, Heather A.
A1 Isaacs, Claudine
YR 2023
UL http://medrxiv.org/content/early/2023/12/04/2023.12.04.23297559.abstract
AB Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint). Secondary endpoints include the presence of ctDNA, toxicity, clinical outcomes at 2-years and association of ctDNA and PIS with clinical outcomes. Forty-five women with TNBC and residual invasive disease after standard neoadjuvant chemotherapy were randomized to nivolumab, capecitabine, or the combination. Here we show that a combination of nivolumab plus capecitabine leads to a greater increase in PIS from baseline to week 6 (91%) compared with nivolumab (47%) or capecitabine (53%) alone (log-rank p = 0.08), meeting the pre-specified primary endpoint. In addition, the presence of circulating tumor DNA (ctDNA) was associated with disease recurrence, with no new safety signals in the combination arm. Our results provide efficacy and safety data on this combination in TNBC and support further development of PIS and ctDNA analyses to identify patients at high risk of recurrence.Competing Interest StatementFL reports consulting/advisory role for AstraZeneca, Pfizer, Merck and Daiichi Sankyo; and institutional research funding from Eisai, AstraZeneca, CytomX and Gilead Sciences. MGM reports consulting/advisory roles for GE and Seagen. GJ reports being a shareholder and employee of NeoGenomics. CG reports serving on advisory boards for AstraZeneca, Daiichi Sankyo and Lilly Oncology. R.Na reports serving on advisory boards for AstraZeneca, BeyondSpring, Fujifilm, GE, Gilead, Infinity, iTeos, Merck, OBI, Oncosec, Sanofi and Seagen; and reports research funding from Arvinas, AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Gilead/Immunomedics, Merck, OBI Pharma, OncoSec, Pfizer, Relay, Seattle Genetics, Sun Pharma and Taiho. ES-R reports serving as a consultant for Lilly, Mylan, Novartis, Immunomedics, AstraZeneca, Seagen, and Merck; and institutional research funding from Susan G. Komen, V Foundation, Breast Cancer Research Foundation of Alabama and the National Institutes of Health. ND, JC and R.Nu report current employment with AstraZeneca. PT reports advisory/consultancy roles for AstraZeneca, Daiichi Sankyo and Lilly. SMT reports a consulting or advisory role for Novartis, Pfizer, Merck, Eli Lilly, AstraZeneca, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, CytomX Therapeutics, Daiichi-Sankyo, Gilead, Ellipses Pharma, 4D Pharma, OncoSec Medical Inc., BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics, ARC Therapeutics, Infinity Therapeutics, Myovant, Zetagen, Umoja Biopharma, Artios Pharma, Menarini/Stemline, Aadi Biopharma, Bayer, Incyte Corp, and Jazz Pharmaceuticals. SMT receives research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, Gilead, NanoString Technologies, Seattle Genetics, and OncoPep. SMS reports serving on advisory boards with honorarium at AstraZeneca, Daiichi-Sankyo, Aventis, Silverback Therapeutics, Genentech/Roche, Merck, Biotheranostics, Natera, Lilly, Molecular Templates and Exact Sciences; institutional research funding from Kailos Genetics and Genentech/Roche; third party in-kind writing from Genentech/Roche and AstraZeneca; and stock and stock options from Seagen. PP reports consulting for BOLT Therapeutics, AbbVie and Perthera; and serving as an unpaid steering committee member of a clinical trial for Seagen. Clinical TrialNCT03487666Funding StatementThis study was supported by research grant P30CA051008-25 from the National Cancer Institute (NCI), the Schulbe Family/Nina Hyde Center for Breast Cancer Research, a Partners in Research grant from Georgetown University, the Intramural Research Program Center for Cancer Research, NCI, the Benderson Family Funds (FL), the Forget Me Not Fund (HAP), and Inivata. Bristol-Myers Squibb provided nivolumab. The funders did not play a role in the study design, data collection and analysis, or manuscript writing. The sponsor investigator is Dr. Filipa Lynce.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The MedStar Georgetown University Hospital Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes